LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 497

Search options

  1. Book ; Online: Mechanisms of neuroinflammation and inflammatory neurodegeneration in acute brain injury

    Kleinschnitz, Christoph / Liesz, Arthur

    2015  

    Abstract: Mechanisms of brain-immune interactions became a cutting-edge topic in systemic neurosciences over the past years. Acute lesions of the brain parenchyma, particularly, induce a profound and highly complex neuroinflammatory reaction with similar ... ...

    Abstract Mechanisms of brain-immune interactions became a cutting-edge topic in systemic neurosciences over the past years. Acute lesions of the brain parenchyma, particularly, induce a profound and highly complex neuroinflammatory reaction with similar mechanistic properties between differing disease paradigms like ischemic stroke, intracerebral hemorrhage (ICH) and traumatic brain injury (TBI). Resident microglial cells sense tissue damage and initiate inflammation, activation of the endothelial brain-immune interface promotes recruitment of systemic immune cells to the brain and systemic humoral immune mediators (e.g. complements and cytokines) enter the brain through the damaged blood-brain barrier. These cellular and humoral constituents of the neuroinflammatory reaction to brain injury contribute substantially to secondary brain damage and neurodegeneration.-

    Diverse inflammatory cascades such as pro-inflammatory cytokine secretion of invading leukocytes and direct cell-cell-contact cytotoxicity between lymphocytes and neurons have been demonstrated to mediate the inflammatory 'collateral damage' in models of acute brain injury. Besides mediating neuronal cell loss and degeneration, secondary inflammatory mechanisms also contribute to functional modulation of neurons and the impact of post-lesional neuroinflammation can even be detected on the behavioral level. The contribution of several specific immune cell subpopulations to the complex orchestration of secondary neuroinflammation has been revealed just recently. However, the differential vulnerability of specific neuronal cell types and the molecular mechanisms of inflammatory neurodegeneration are still elusive. Furthermore, we are only on the verge of characterizing the control of long-term recovery and neuronal plasticity after brain damage by inflammatory pathways.-

    Yet, a more detailed but also comprehensive understanding of the multifaceted interaction of these two supersystems is of direct translational relevance. Immunotherapeutic strategies currently shift to the center of translational research in acute CNS lesion since all clinical trials investigating direct neuroprotective therapies failed. To advance our knowledge on brain-immune communications after brain damage an interdisciplinary approach covered by cellular neuroscience as well as neuroimmunology, brain imaging and behavioral sciences is crucial to thoroughly depict the intricate mechanisms
    Keywords Neurosciences. Biological psychiatry. Neuropsychiatry ; Science (General)
    Size 1 electronic resource (284 p.)
    Publisher Frontiers Media SA
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT020091128
    ISBN 9782889196913 ; 2889196917
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  2. Book: Spinale Muskelatrophie

    Kleinschnitz, Christoph / Hagenacker, Tim / Hermann, Andreas / Günther, René / Kamm, Christoph / Walter, Maggie C. / Weiler, Markus / Wurster, Claudia

    Expertenempfehlungen zur Behandlung von erwachsenen Patienten mit Nusinersen

    (Therapie Report spezial ; 7. Jahrgang, Heft 1 (September 2019))

    2019  

    Author's details Herausgeber [und Autoren] Prof. Dr. Christoph Kleinschnitz. Autoren: Priv.-Doz. Dr. med. Tim Hagenacker, Prof. Dr. med. Dr. rer. med. Andreas Hermann, Dr. med. René Günther, Priv.-Doz. Dr. med. Christoph Kamm, Prof. Dr. med. Maggie C. Walter, Priv.-Doz. Dr. med. Markus Weiler, Dr. med. Claudia Wurster
    Series title Therapie Report spezial ; 7. Jahrgang, Heft 1 (September 2019)
    Therapie Report Spezial
    Collection Therapie Report Spezial
    Language German
    Size 11 Seiten, Illustrationen, Diagramme
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Book
    HBZ-ID HT020360318
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  3. Article: Nervenheilkunde

    Kleinschnitz, Christoph

    Nervenheilkunde

    2020  Volume 39, Issue 03, Page(s) 123–123

    Language German
    Publishing date 2020-03-01
    Publisher © Georg Thieme Verlag KG Stuttgart · New York
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2223503-6
    ISSN 2567-5788 ; 0722-1541
    ISSN (online) 2567-5788
    ISSN 0722-1541
    DOI 10.1055/a-1016-2162
    Database Thieme publisher's database

    More links

    Kategorien

  4. Book ; Thesis: Verteilung und subzelluläre Lokalisation des Stickstoffmonoxid-Rezeptorenzyms, lösliche Guanylylcyclase

    Kleinschnitz, Christoph

    2001  

    Author's details vorgelegt von Christoph Kleinschnitz
    Language German
    Size 93 Bl., Ill., graph. darst.
    Edition [Mikrofiche-Ausg.]
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Würzburg, Univ., Diss., 2001
    HBZ-ID HT013236041
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  5. Article ; Online: Treatment of Adult Spinal Muscular Atrophy: Overview and Recent Developments.

    Brakemeier, Svenja / Stolte, Benjamin / Kleinschnitz, Christoph / Hagenacker, Tim

    Current pharmaceutical design

    2022  Volume 28, Issue 11, Page(s) 892–898

    Abstract: Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease leading to progressive and, in many cases, severe muscle weakness and atrophy in the natural disease course. An increasing number of gene-based treatment options have become available ... ...

    Abstract Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease leading to progressive and, in many cases, severe muscle weakness and atrophy in the natural disease course. An increasing number of gene-based treatment options have become available in recent years. Growing knowledge regarding the underlying genetic mechanisms makes the disease well amenable to them. Over the past few years, data on new treatments, their mechanisms of action and therapeutic outcomes have been published, reflecting the current dynamics in this field. With the approval of the antisense oligonucleotide nusinersen, the vector-based therapy with onasemnogene abeparvovec and the small molecule splicing modifier risdiplam, three gene therapeutic drugs are available for the treatment of SMA showing improvement in motor function. But in the pivotal studies, several relevant parameters have not been addressed. There is a data gap for the treatment outcome of adult individuals with SMA as well as for several other relevant outcome parameters, like bulbary or ventilatory function. With increasing treatment options, additional individual therapies have become necessary. Studies on combination therapies or switch of therapy, e.g., the sequential administration of onasemnogen abeparvovec and nusinersen, are necessary. An overview of current developments in the field of therapeutic options for adult SMA is presented. Important characteristics of each therapeutic options are discussed so that the reader can comprehend underlying pathophysiological mechanisms as well as advantages and disadvantages of each therapy. The focus is on gene-based treatment options, but options beyond this are also addressed.
    MeSH term(s) Genetic Therapy ; Humans ; Muscular Atrophy, Spinal/drug therapy ; Muscular Atrophy, Spinal/genetics ; Oligonucleotides, Antisense/therapeutic use ; RNA Splicing ; Treatment Outcome
    Chemical Substances Oligonucleotides, Antisense
    Language English
    Publishing date 2022-03-30
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 1304236-1
    ISSN 1873-4286 ; 1381-6128
    ISSN (online) 1873-4286
    ISSN 1381-6128
    DOI 10.2174/1381612828666220329115433
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: "Wir sehen auch bei Erwachsenen mit SMA messbare Verbesserungen". Prof. Dr. Christoph Kleinschnitz vom Universitätsklinikum Essen im Interview zur Therapie der spinalen Muskelatrophie

    Kleinschnitz, Christoph

    Der Neurologe & Psychiater

    2018  Volume 19, Issue 3, Page(s) 18

    Language German
    Document type Article
    ZDB-ID 2036795-8
    ISSN 1616-2455
    Database Current Contents Medicine

    More links

    Kategorien

  7. Book ; Online ; Thesis: Untersuchung zur pathophysiologischen Rolle und therapeutischen Relevanz der neuen Inhibitoren der plasmatischen Blutgerinnung Agaphelin und Ixolaris im experimentellen Schlaganfallmodell der Maus

    Leinweber, Jonas [Verfasser] / Kleinschnitz, Christoph [Gutachter]

    2022  

    Author's details Jonas Leinweber ; Gutachter: Christoph Kleinschnitz
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universität Würzburg
    Publishing place Würzburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  8. Article ; Online: Thrombomodulin, a Master Switch Controlling Poststroke Microvascular Remodeling and Angiogenesis.

    Hermann, Dirk M / Kleinschnitz, Christoph

    Arteriosclerosis, thrombosis, and vascular biology

    2020  Volume 40, Issue 12, Page(s) 2818–2820

    MeSH term(s) Brain/metabolism ; Humans ; Neovascularization, Pathologic ; Receptors, Thrombin ; Thrombin/metabolism ; Thrombomodulin/metabolism
    Chemical Substances Receptors, Thrombin ; THBD protein, human ; Thrombomodulin ; Thrombin (EC 3.4.21.5)
    Language English
    Publishing date 2020-11-24
    Publishing country United States
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/ATVBAHA.120.315425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy?

    Szepanowski, Fabian / Schoser, Benedikt / Mausberg, Anne K / Kleinschnitz, Christoph / Hartung, Hans-Peter / Stettner, Mark

    Brain and behavior

    2023  Volume 13, Issue 11, Page(s) e3256

    Abstract: Standardized pharmacological response tests are important and established diagnostic tools in the field of neurology. However, regarding therapeutic responses to intravenous immunoglobulins (IVIg) in CIDP, neither a definition of therapeutic response has ...

    Abstract Standardized pharmacological response tests are important and established diagnostic tools in the field of neurology. However, regarding therapeutic responses to intravenous immunoglobulins (IVIg) in CIDP, neither a definition of therapeutic response has been established, nor a response test has been suggested so far. Here we suggest a practical clinical approach which is supported by current literature in the field. An established standardized IVIg response test could avoid prolonged therapy without benefit for the patient and ensure a timely therapy switch or treatment escalation if required. This approach would also be advantageous due to the global scarcity of plasma derivatives as a human resource and could be the foundation to be adjusted and improved by subsequent studies.
    MeSH term(s) Humans ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/therapy ; Immunoglobulins, Intravenous/therapeutic use ; Administration, Intravenous
    Chemical Substances Immunoglobulins, Intravenous
    Language English
    Publishing date 2023-09-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2623587-0
    ISSN 2162-3279 ; 2162-3279
    ISSN (online) 2162-3279
    ISSN 2162-3279
    DOI 10.1002/brb3.3256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Dimethyl Fumarate Attenuates Lymphocyte Infiltration and Reduces Infarct Size in Experimental Stroke.

    Schuhmann, Michael K / Langhauser, Friederike / Zimmermann, Lena / Bellut, Maximilian / Kleinschnitz, Christoph / Fluri, Felix

    International journal of molecular sciences

    2023  Volume 24, Issue 21

    Abstract: Ischemic stroke is associated with exacerbated tissue damage caused by the activation of immune cells and the initiation of other inflammatory processes. Dimethyl fumarate (DMF) is known to modulate the immune response, activate antioxidative pathways, ... ...

    Abstract Ischemic stroke is associated with exacerbated tissue damage caused by the activation of immune cells and the initiation of other inflammatory processes. Dimethyl fumarate (DMF) is known to modulate the immune response, activate antioxidative pathways, and improve the blood-brain barrier (BBB) after stroke. However, the specific impact of DMF on immune cells after cerebral ischemia remains unclear. In our study, male mice underwent transient middle cerebral artery occlusion (tMCAO) for 30 min and received oral DMF (15 mg/kg) or a vehicle immediately after tMCAO, followed by twice-daily administrations for 7 days. Infarct volume was assessed on T2-weighted magnetic resonance images on days 1 and 7 after tMCAO. Brain-infiltrating immune cells (lymphocytes, monocytes) and microglia were quantified using fluorescence-activated cell sorting. DMF treatment significantly reduced infarct volumes and brain edema. On day 1 after tMCAO, DMF-treated mice showed reduced lymphocyte infiltration compared to controls, which was not observed on day 7. Monocyte and microglial cell counts did not differ between groups on either day. In the acute phase of stroke, DMF administration attenuated lymphocyte infiltration, probably due to its stabilizing effect on the BBB. This highlights the potential of DMF as a therapeutic candidate for mitigating immune cell-driven damage in stroke.
    MeSH term(s) Male ; Mice ; Animals ; Dimethyl Fumarate/pharmacology ; Dimethyl Fumarate/therapeutic use ; Stroke/pathology ; Brain Ischemia/metabolism ; Infarction, Middle Cerebral Artery/complications ; Brain/metabolism ; Mice, Inbred C57BL
    Chemical Substances Dimethyl Fumarate (FO2303MNI2)
    Language English
    Publishing date 2023-10-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms242115540
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top